Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach.
Lalagkas PN, Iliou J, Rigo R, Miarons M, Fernández-Alarcon B, Bestard O, Cruzado JM, Melilli E, Torras J, Grinyó JM, Lloberas N, Colom H. Lalagkas PN, et al. Among authors: colom h. Clin Pharmacokinet. 2023 Jun;62(6):861-880. doi: 10.1007/s40262-023-01237-3. Epub 2023 May 4. Clin Pharmacokinet. 2023. PMID: 37140726 Free PMC article.
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, Lloberas N, Pou L, Peraire C, Grinyó JM. Caldés A, et al. Among authors: colom h. Antimicrob Agents Chemother. 2009 Nov;53(11):4816-24. doi: 10.1128/AAC.00085-09. Epub 2009 Sep 8. Antimicrob Agents Chemother. 2009. PMID: 19738014 Free PMC article. Clinical Trial.
Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM. Caldés A, et al. Among authors: colom h. Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9. Transpl Infect Dis. 2010. PMID: 20002612 Clinical Trial.
Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.
Llaudó I, Colom H, Giménez-Bonafé P, Torras J, Caldés A, Sarrias M, Cruzado JM, Oppenheimer F, Sánchez-Plumed J, Gentil MÁ, Ekberg H, Grinyó JM, Lloberas N. Llaudó I, et al. Among authors: colom h. Transpl Int. 2013 Feb;26(2):177-86. doi: 10.1111/tri.12018. Epub 2012 Dec 7. Transpl Int. 2013. PMID: 23216707 Free article.
Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
Martin-Liberal J, Gil-Martín M, Sáinz-Jaspeado M, Gonzalo N, Rigo R, Colom H, Muñoz C, Tirado OM, García del Muro X. Martin-Liberal J, et al. Among authors: colom h. Br J Cancer. 2014 Aug 26;111(5):858-65. doi: 10.1038/bjc.2014.370. Epub 2014 Jul 8. Br J Cancer. 2014. PMID: 25003665 Free PMC article. Clinical Trial.
62 results